Alzheimer's patients tend to have CAA (Cerebral Amyloid Angiopathy) where beta amyloid plaques replace the smooth muscle of blood vessels in the brain. Since the drug (lecanemab) works by removing these plaques, damage to the affected blood vessels results in inflammation, swelling, hemorrhage and eventually death.